Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib
Yu Feng(Tianjin Medical University), Yuhuan Zheng(Sichuan University)
Cited by 5
Related Papers
Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research
|Anti-Cancer Drugs|2022|120
Active commuting and the risk of obesity, hypertension and diabetes: a systematic review and meta-analysis of observational studies
|BMJ Global Health|2021|26
FADD regulates adipose inflammation, adipogenesis, and adipocyte survival
|Cell Death Discovery|2024|7
Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3
|Journal of Cancer Research and Clinical Oncology|2024|1